"name","rationale","uuid:ID","description","instanceType","id","label"
"Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","58131fa5-a0cd-4242-bac3-184f5c44d47a","The main design for the study","StudyDesign","StudyDesign_1",""
